ISRAEL'S OPTIMATA IN PHARMACEUTICAL COLLABORATION WITH LILLY

A A

Optimata Ltd., a science-based, interdisciplinary company, dedicated to the development of predictive bio simulation technologies, announced the completion of the first phase of a pilot collaboration project with Eli Lilly & Co. The project uses Optimata's Virtual Patient Technology to assist in the clinical trial design of a novel anti-cancer cytotoxic compound. "We are excited to have this opportunity to work with a leading pharmaceutical manufacturer like Eli Lilly," said Guy Malchi, President of Optimata. The virtual patient technology is a computer generated method that predicts how patients will respond to a compound.

Israel121c.org (http://www.israel21c.org/bin/en.jsp?enDispWho=InThePress&enPage=BlankPage&enDisplay=view&enDispWhat=Zone&enZone=InThePress&Date=03/29/06)